X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire•04/11/2026•16:15 ET
0
Key Highlights
- ➤4WARD enrollment of 126 participants expected complete in Q4 2026
- ➤4WARD and 4STEPS topline data expected in Q1 2028
- ➤4STEPS Phase 2b trial targets G-CSF dose reduction in approximately 25 patients
- ➤Cash, equivalents and marketable securities totaled $187.7 million at September 30
- ➤Senior term loan facility provides up to $150 million from K2 HealthVentures
Expert Statements
Adam Craig, Executive Chairman of X4 Pharmaceuticals
“With topline data from both our global 4WARD trial and our new 4STEPS trial expected in the first quarter of 2028, we believe mavorixafor is uniquely positioned to transform the treatment landscape for patients with primary chronic neutropenia.”
Adam Craig, Executive Chairman of X4 Pharmaceuticals
“We have made significant progress enrolling our 4WARD trial and remain on track to complete our target enrollment of 126 participants by the end of this year.”
Adam Craig, Executive Chairman of X4 Pharmaceuticals
“At our recent, well-received Investor Day, we outlined the design of our Phase 2b 4STEPS trial designed to evaluate how to safely reduce G-CSF dosage after starting mavorixafor while maintaining stable neutrophil counts.”
Adam Craig, Executive Chairman of X4 Pharmaceuticals
“We also shared new market research supporting the significant commercial opportunity in this disease targeting 15,000 to 30,000 patients in the United States, subject to FDA labeling.”
- 4WARD Phase 3 Chronic Neutropenia Trial Expected to Achieve Target Enrollment in Q4 2026 -
- Initiating 4STEPS Phase 2b Trial Evaluating G-CSF Dose Reduction with Mavorixafor; Enrollment of First Participant Expected in Q1 2027 -
Get started
Create a free account to read the full story.